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a b s t r a c t
Alphavirus-based replicons are a promising nucleic acid vaccine platform characterized by robust gene
expression and immune responses. To further explore their use in vaccination, replicons were
engineered to allow conditional control over their gene expression. Riboswitches, comprising a ribozyme
actuator and RNA aptamer sensor, were engineered into the replicon 30 UTR. Binding of ligand to
aptamer modulates ribozyme activity and, therefore, gene expression. Expression from DNA-launched
and VRP-packaged replicons containing riboswitches was successfully regulated, achieving a 47-fold
change in expression and modulation of the resulting type I interferon response. Moreover, we
developed a novel control architecture where riboswitches were integrated into the 30 and 50 UTR of
the subgenomic RNA region of the TC-83 virus, leading to an 1160-fold regulation of viral replication. Our
studies demonstrate that the use of riboswitches for control of RNA replicon expression and viral
replication holds promise for development of novel and safer vaccination strategies.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Alphaviruses have a positive-sense, single-stranded RNA genome
that has a 50 7-methylguanylate cap and 30 polyA tail. Viral non-
structural proteins necessary for nucleic acid replication are encoded
at the 50 end of the genome and immediately translated upon genome
delivery to the cytoplasm of the cell. In addition to the generation of
new genomic RNA, these proteins also transcribe a subgenomic mRNA
from which the viral structural proteins are translated. The subge-
nomic RNA is generated at a level at least 3-fold greater than the
genomic RNA, leading to abundant structural protein expression and
assembly of new virions (Kuhn, 2007). The high level of protein
expression achieved by alphaviruses has been utilized for vaccination
strategies by modifying the genome to replace the structural proteins
with antigen(s) of interest in the subgenomic RNA (Rayner et al.,
2002). These alphavirus-based replicons have been shown to provide
robust antigen expression and elicit strong immune responses
(Ljungberg and Liljestrom, 2015). Clinical trials have been reported
using alphavirus replicon particles as vaccines against infectious
diseases such as HIV-1 and CMV, as well as cancers such as prostate
and colorectal carcinoma (Bernstein et al., 2009; Morse et al., 2010;
Slovin et al., 2013; Wecker et al., 2012). Results of these trials have
demonstrated that alphavirus replicon vaccines are safe and immuno-
genic, generating both antibody and T cell responses (Bernstein et al.,
2009; Morse et al., 2010).
To further explore the use of replicons for vaccination, it would be
advantageous to regulate antigen expression from the replicon in
order to modulate the resultant immune responses. For example, if
gene expression could be turned on and off as needed, a novel prime-
boost strategy might be established inwhich only one injection of the
vaccine would permit controlled priming and boosting of the immune
responses. Modifying the duration of expression during priming and/
or the timing of booster injection may lead to the generation of a
more robust and highly functional response. Recent studies have
shown that synthetic RNA-regulatory elements called riboswitches
can be used to control gene expression from mRNA (Chang et al.,
2012). One class of engineered riboswitch molecules consists of a
sensor domain comprised of an RNA aptamer and an actuator domain
comprised of a ribozyme (Win and Smolke, 2007). By changing the
RNA aptamer in the sensor domain, switches have been engineered
to respond to different small molecules, such as theophylline and
tetracycline. This ribozyme–aptamer switch is incorporated into the 30
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untranslated region (UTR) of a target mRNA, where ligand binding at
the sensor domain leads to modulation of ribozyme cleavage and
ultimately expression of the target gene (Auslander et al., 2010;
Nomura et al., 2013; Win and Smolke, 2007).
Riboswitches have been used in numerous studies to program
cells, including bacteria, yeast, and mammalian cells, to respond to
a speciﬁc input ligand and produce a biologically signiﬁcant
phenotypic output (Liang et al., 2011). One clinically relevant
example of this involves the use of a ribozyme–aptamer switch
in T cells to control cell survival and proliferation (Chen et al.,
2010). In these studies, a riboswitch was placed in the 30 UTR of a
transcript encoding IL-15, a cytokine that induces T cell survival,
proliferation, and long-term persistence (Berger et al., 2008; Hsu
et al., 2005). In the presence of the effector drug, T cell viability
and proliferation were substantially enhanced both in vitro upon
transfection and in vivo after injection of T cells stably expressing
the riboswitch system in mice (Chen et al., 2010). This type of
approach could be particularly useful in adoptive T cell therapies
to extend the survival and proliferation of T cells to sufﬁciently
eliminate diseased cells, and it could also serve as a fail-safe switch
to shut down overactive T cells. Riboswitches may also be
implemented as safety switches to terminate replication of viruses,
such as oncolytic and live-attenuated vaccine viruses, to enhance
their safety. It has been shown that insertion of riboswitches into
the untranslated genomic regions of viral genes in both an
oncolytic adenovirus and measles virus led to a signiﬁcant
decrease in viral protein expression and replication upon addition
of modulating ligand (Ketzer et al., 2014).
In this study, we used engineered riboswitches to control gene
expression from an alphavirus replicon derived from Venezuelan
equine encephalitis virus (VEEV) vaccine strain TC-83 (Kinney
et al., 1993). These riboswitches were developed from the ham-
merhead ribozyme from the satellite RNA of tobacco ringspot virus
(sTRSV) conjugated to a theophylline aptamer (Win and Smolke,
2007). Multiple different variants of this switch have been
designed to facilitate activation or inactivation of the ribozyme
upon addition of theophylline (Liang et al., 2012; Win and Smolke,
2007). By insertion of these riboswitches into the TC-83 replicon,
we were able to temporally control antigen expression, as well as
modulate the type I IFN response induced by these replicons.
Finally, using this switch system, we were able to effectively
control the replication of the parental TC-83 vaccine virus,
demonstrating the feasibility of the use of this system as viral
vaccine safety-switches.
Results
Design of replicons with controllable gene expression
TC-83-based, DNA-launched replicons were engineered to con-
tain various riboswitches in their 30 UTR (Fig. 1A). These constructs
use the CMV promoter to drive initial expression of the replicon,
which is followed by autonomous replication of the RNA. The
riboswitches act to control gene expression by regulating cleavage
of the RNA in response to theophylline (Win and Smolke, 2007).
Fig. 1B shows the different riboswitches inserted into the 30 UTR of
the replicon, as well as their predicted effect on gene expression
with and without theophylline. For replicons containing an ON
switch, the ribozyme is able to form its active conformation in the
absence of theophylline so gene expression is inhibited. However,
upon binding of theophylline to its aptamer sequence, the structure
of the riboswitch is altered. This leads to a shift in the aptamer
domain and causes a bulge in the ribozyme structure rendering it
inactive and, therefore, allowing gene expression to occur (Fig. 1B).
Conversely, for replicons containing an OFF switch, the structure of
the ribozyme is disrupted in the absence of theophylline, rendering
it inactive. However, binding of theophylline shifts the structure of
the riboswitch, allowing the ribozyme to form its active conforma-
tion to cleave the RNA and, therefore, lower gene expression
(Fig. 1B). Numerous different ON and OFF switches have been
developed and optimized by modifying the structure of the aptamer
and actuator domains using both rational tuning strategies (Win
and Smolke, 2007) and high-throughput screening (Liang et al.,
2012). In addition to the replicons shown in Fig. 1B, replicons
containing active and inactive sTRSV ribozymes were generated as
controls. For replicons containing an active ribozyme, gene expres-
sion is always inhibited because the ribozyme is constitutively
active and thus continuously cleaves the RNA regardless of the
addition of theophylline. For replicons containing an inactive
ribozyme, gene expression is constantly on, regardless of theophyl-
line, because point mutations in the active site of the ribozyme
disable its ability to cleave the RNA (Win and Smolke, 2007). We
sought to test these switches in our replicon system, hypothesizing
that the use of riboswitches could achieve highly efﬁcient regula-
tion of gene expression.
Riboswitch-mediated regulation of DNA-launched TC-83 replicon
gene expression
DNAs encoding replicons expressing SEAP and containing ribos-
witches or ribozyme controls in their 30 UTR were transfected into BHK
cells. These cells were treated with or without 4mM theophylline 24 h
posttransfection, and media were collected at 0, 8, and 24 h post-
theophylline treatment to determine SEAP expression. As expected, a
control DNA encoding a replicon containing the active ribozyme
produced almost undetectable expression regardless of theophylline
treatment, consistent with the constitutive activity of the ribozyme
(Fig. 2A). Furthermore, transfection with a DNA encoding a replicon
containing the inactive ribozyme showed efﬁcient expression, inde-
pendent of theophylline treatment (Fig. 2A), although addition of
Fig. 1. Schematic of replicon and riboswitches. (A) Schematic showing the DNA-
launched TC-83 replicon with a riboswitch in the 30 UTR. The replicon is launched
from the cytomegalovirus (CMV) promoter. NSP1–NSP4 indicate the non-structural
genes. SEAP, secreted alkaline phosphatase. The subgenomic promoter is indicated
by the arrow. (B) Schematic showing the types of switches inserted into the 30 UTR
of the replicon. ON switches exhibit active ribozyme cleavage in the absence of
theophylline, but when theophylline is added the ribozyme structure is disrupted
and cleavage is inhibited, turning gene expression ON. OFF switches inhibit
ribozyme cleavage in the absence of theophylline, but addition of theophylline
allows the ribozyme to form its active conformation and initiate cleavage, turning
gene expression OFF. Color scheme: ribozyme, blue; theophylline aptamer, orange;
theophylline, red circle; arrow, cleavage site.
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theophylline appeared to non-speciﬁcally enhance SEAP expression by
1.2-fold at 24 h posttreatment.
Fig. 2B shows the data collected from theophylline-treated cells
transfected with DNAs encoding replicons containing two different
ON switches. Expression for each switch-containing construct was
normalized to that observed for the replicon containing the inactive
ribozyme control with and without theophylline treatment at each
time point. The replicon containing the ON switch L2b8 (described
in Ref. (Win and Smolke, 2007)) showed only a 10% increase in
expression with addition of theophylline at 24 h posttreatment.
However, the replicon containing the ON switch L2b8-a1 (described
in Ref. (Liang et al., 2012)) showed a 3.1-fold increase in gene
expression at 24 h with theophylline treatment. This enhanced
switching of expression relative to the L2b8 switch was due to a
decrease in the background expression observed without theophyl-
line treatment. While the replicon containing L2b8 showed 90%
expression in the absence of theophylline compared to the inactive
ribozyme control at 24 h, the replicon containing L2b8-a1 showed
reduced background expression at only 30%, which indicates that
L2b8-a1 efﬁciently suppresses gene expression in the absence of
theophylline. Upon addition of theophylline, this replicon achieved
successful activation of expression equal to 100% of the inactive
ribozyme control at 24 h posttreatment.
We next aimed to generate multi-copy switch architecture to
further increase the stringency of regulation of gene expression. To
accomplish this, 2 copies of the ON switch L2b8-a1 were inserted in
tandem into the 30 UTR of the replicon. Upon transfection into BHK
cells and treatment with theophylline, this replicon produced a 47-fold
Fig. 2. DNA-launched TC-83 replicon expression can be regulated by riboswitches. DNA-launched replicons containing (A) the wild-type sTRSV ribozyme or an inactive form
of the sTRSV ribozyme, (B) the ON riboswitches L2b8 or L2b8-a1, (C) 2 copies of the ON riboswitch L2b8-a1, or (D) 1–3 copies of the OFF riboswitch L2bOFF1, were transfected
into BHK cells and 24 h later treated with media 74 mM theophylline. Supernatants were collected at 0, 8, and 24 h posttheophylline addition and assayed for SEAP
expression. *Po0.001 when compared to 0 mM Theo.
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increase in expression (Fig. 2C) at 24 h posttreatment. This enhanced
regulation was largely due to the reduction in background expression.
Adding this second copy of L2b8-a1 signiﬁcantly reduced the back-
ground of expression in the absence of theophylline to 3% expression
compared to the inactive ribozyme control.
In attempt to shutdown gene expression, 1, 2, or 3 tandem copies
of the OFF switch L2bOFF1 (described in Ref. (Win and Smolke,
2007)) were inserted into the 30 UTR of the replicon (Fig. 2D).
Inserting 1 copy of this OFF switch into the replicon resulted in a
1.3-fold decrease in expression 24 h after addition of theophylline.
Adding a second or third copy of the switch enhanced the down-
regulation of expression to 1.8-fold or 3.5-fold upon theophylline
treatment, respectively. Expression of the replicon containing 3 copies
of L2bOFF1 was successfully reduced by theophylline addition to
about 25% compared to the inactive ribozyme control at 24 h
posttreatment. Together, these data show that replicon expression
can be successfully regulated by both ON and OFF riboswitches,
leading to signiﬁcant activation and inactivation, respectively, of gene
expression.
Riboswitch-regulated gene expression of VRP-packaged replicons
Next, we wanted to determine if replicon expression could be
regulated when delivered as viral particles. Replicons expressing
SEAP and containing either riboswitches or the inactive ribozyme
control in their 30 UTR were packaged into viral replicon particles
(VRPs), as described in Materials and methods section. These VRPs
were then used to infect BHK cells and treated with or without
4 mM theophylline. SEAP expression was determined 20 h after
infection (Fig. 3A). VRPs containing either 1 copy or 2 copies of the
ON switch L2b8-a1 showed a 3.8 to 4-fold increase in expression
with addition of theophylline. Background expression for these
VRPs in the absence of theophylline was close to that of the
negative control (i.e., no VRP). VRPs containing 1 copy of the OFF
switch L2bOFF1 did not show a signiﬁcant difference in expression
with or without theophylline treatment, which was consistent
with the result seen with the DNA-launched replicon (Fig. 2D).
However, a 1.7-fold decrease in expression was observed for the
VRPs containing 3 copies of the L2bOFF1 switch when treated with
theophylline.
In addition, RNA copy number was analyzed after VRP infection
for both genomic and subgenomic RNA to determine whether
riboswitch cleavage impacts replicon RNA synthesis (Fig. S1A and
B). A signiﬁcant increase in the level of genomic RNAwas observed
in cells infected with VRPs containing 2 copies of the ON switch
L2b8-a1 with addition of theophylline (Fig. S1A). The amount of
subgenomic RNA present in these infected cells also increased
upon addition of theophylline, although not to statistical signiﬁ-
cance (Fig. S1B). Conversely, a signiﬁcant decrease in the level of
genomic RNA was observed in cells infected with VRPs containing
3 copies of the OFF switch L2bOFF1 upon addition of theophylline
(Fig. S1A). Moreover, the amount of subgenomic RNA in cells
infected with VRPs containing 3 copies of L2bOFF1 also showed a
signiﬁcant decrease upon theophylline treatment (Fig. S1B). These
data suggest that the insertion of riboswitches into the 30 UTR
allows the regulation of synthesis of both genomic and subge-
nomic RNA, consistent with the observed transgene expression.
We also aimed to determine whether VRP-mediated gene expres-
sion could be shut down once it had been established. To test this,
BHK cells were infected with VRP-packaged replicons containing
either 1 or 3 copies of the OFF switch L2bOFF1 or the inactive
ribozyme control. Twelve hours later, cells were treated with or
without 4 mM theophylline and SEAP expression was determined at
both 0 and 8 h posttheophylline treatment (Fig. 3B). As anticipated,
expression at 0 h posttheophylline addition was similar for all cells
infected with VRPs containing either 1 or 3 copies of the OFF switch.
However, at 8 h posttreatment, the VRPs containing 1 copy of the OFF
switch showed a trend toward a decrease in expression with addition
of theophylline. Importantly, the VRPs containing 3 copies of the OFF
switch showed a larger, more signiﬁcant downregulation in expres-
sion. The amount of replicon genomic and subgenomic RNA in cells
infected with these VRPs was unchanged upon theophylline treat-
ment (Fig. S1C and D). This is not surprising because a high level of
RNA replication was already established before theophylline treat-
ment. Although lacking the ability to drive transgene expression, RNA
cleaved by theophylline-activated riboswitches was unlikely to be
signiﬁcantly cleared from the cells after only 8 h. Overall, these data
demonstrate that the expression of riboswitch-containing replicons
delivered as VRPs can also be successfully regulated by theophylline.
Regulation of the IFN response to DNA-launched and VRP-packaged
replicons
A key goal of this study is to generate controllable replicons
that can modulate the immune response. To test this in an in vitro
model system, we sought to determine whether we could regulate
the type I IFN response by using riboswitch-containing replicons.
To establish our model system, mouse embryonic ﬁbroblast (MEF)
cells were transduced with a lentiviral vector expressing the ﬁreﬂy
luciferase gene under the control of tandem repeats of the IFN-
stimulated response element (ISRE). These cells produce luciferase
in response to type I IFN, which is used as a readout for the
magnitude of the IFN response. In our study, these cells were
transfected with DNA-launched replicons (Fig. 4A) or infected with
VRP-packaged replicons (Fig. 4B) and treated with or without
theophylline. Luciferase expression was assayed 20 h after trans-
fection or infection to determine whether theophylline addition
Fig. 3. VRP expression can also be regulated by riboswitches. (A) VRP-packaged
replicons expressing SEAP and encoding riboswitches in their 30 UTR were used to
infect BHK cells at an MOI of 0.1 and treated with or without 4 mM theophylline.
Supernatants were collected 20 h later and assayed for SEAP expression. (B) BHK
cells were infected with VRP-packaged replicons containing 1–3 copies of the OFF
switch L2bOFF1 or VRPs containing the inactive ribozyme control, and incubated
for 12 h. Cells were then treated with or without 4 mM theophylline to determine
whether expression can be shut down. Supernatants were collected at 0 h and 8 h
posttheophylline treatment and assayed for SEAP expression. Neg¼ Negative
control (i.e., no VRP). *Po0.01; **Po0.001.
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leads to modulation of the type I IFN response. Similar results
were observed for both the DNA-launched replicons and VRPs,
although the degree of difference in the response was more
pronounced for the VRPs (Fig. 4A and B). The replicon containing
1 copy of the ON switch L2b8-a1 showed 20% or 65% upregulation
in the IFN response with theophylline addition for the DNA-
launched replicon or VRPs, respectively. This upregulation was
doubled for the replicon containing 2 copies of the ON switch with
theophylline treatment, largely by reducing the background IFN
response (in the absence of theophylline treatment) to the levels
similar to the Negative control. The background IFN response
observed for the DNA-launched replicon is likely due to the
Lipofectamine used for transfection. The replicon containing 1 copy
of the OFF switch L2bOFF1 did not show a signiﬁcant difference in
the IFN response with or without theophylline treatment. How-
ever, the replicon containing 3 copies of L2bOFF1 exhibited a
signiﬁcant decrease in the IFN response with theophylline treat-
ment for both the DNA-launched replicon and the VRP-packaged
replicon (Fig. 4A and B).
We next sought to determine whether the IFN response can be
modulated over time (Fig. 4C), as this would be important for a
vaccination strategy in which only one injection of the replicon is
needed for controlled priming and boosting of the immune
response. The MEF cells were transfected with the DNA-launched
replicon containing either 2 copies of the ON switch L2b8-a1 or the
inactive ribozyme control and incubated for 24 h. The baseline IFN
response at 24 h posttransfection, before theophylline treatment,
(i.e., 0 h post- 7theophylline) was about 45% compared to the
inactive ribozyme control, which is consistent with the results in
Fig. 4A. Cells were then treated with or without theophylline and
luciferase expression was determined 8 hafter. The cells treated
with theophylline had a signiﬁcant increase in the IFN response
compared to the cells left untreated. The theophylline was then
removed and luciferase expression was determined again 12 h later.
As anticipated, the IFN response was reduced to a level similar to
the untreated cells. When theophylline was added again, the IFN
response 8 h later showed a signiﬁcant increase compared to the
untreated cells (Fig. 4C). This ability to modulate the type I IFN
response over time suggests that these riboswitch-containing
replicons may be capable of controlling the immune response to
their encoded antigen in vivo.
Replicon gene expression can be regulated with different riboswitches
To demonstrate the versatility of this switch platform, we aimed to
determine whether alternative riboswitches could be swapped into the
replicon. Previously, an OFF riboswitch developed using the hepatitis
delta virus (HDV) genomic ribozyme conjugated to a theophylline
aptamer has also been reported (Nomura et al., 2013). To test this
switch in our replicon system, we inserted the optimized switch
Theo6HDV or an inactive HDV ribozyme control (Nomura et al.,
2013) into the 30 UTR of a replicon expressing SEAP. These replicons
were then delivered to BHK cells by either transfection of DNA-
launched replicons (Fig. S2A) or infection with VRP-packaged replicons
(Fig. S2B) and treated with or without theophylline. Theophylline
addition decreased expression approximately 3-fold for the DNA-
launched replicon and 2-fold for the VRPs containing the Theo6HDV
switch when normalized to the replicon containing the inactive HDV
ribozyme. These replicons were also tested for their ability to regulate
the type I IFN response. MEF cells were either transfected with the
DNA-launched replicons (Fig. S2C) or infected with the VRP-packaged
replicons (Fig. S2D) and treated with or without theophylline. Addition
Fig. 4. The IFN response to DNA-launched replicons and VRPs containing riboswitches can be modulated by theophylline addition. Mouse embryonic ﬁbroblast (MEF) cells
were transduced with a lentiviral vector expressing the ﬁreﬂy luciferase gene under the control of a minimal CMV promoter and tandem repeats of the IFN-stimulated
response element (ISRE). Stably transduced cells were selected with puromycin. These cells were (A) transfected with DNA-launched replicons containing riboswitches or
(B) infected with VRPs containing riboswitch-bearing replicons at an MOI of 1 and treated with or without 4 mM theophylline. The type I IFN response was determined
20 h later by measuring luciferase expression. Lipo¼Lipofectamine. Neg¼Negative control (i.e., no VRP). **Po0.001; *Po0.05. (C) To examine the modulation of the IFN
response over time, the MEF cells were transfected with the DNA-launched replicon containing 2 copies of the L2b8-a1 ON switch or the DNA-launched replicon containing
the inactive ribozyme control. 24 h later, cells were treated 74 mM theophylline, followed by removal of theophylline after 8 h, and then treatment again 7theophylline
after an additional 12 h. The IFN response was determined at 0, 8, 20, and 28 h posttreatment by measuring luciferase expression. *Po0.01 when compared to the no Theo
control.
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of theophylline signiﬁcantly decreased the IFN response for both the
DNA-launched replicon and the VRPs containing the switch. This
demonstrates that alternative riboswitches can be readily swapped
into the 30 UTR of the replicon and lead to efﬁcient regulation of gene
expression, and resulting immune modulation.
Riboswitch-mediated control of TC-83 virus replication
An additional important application of these riboswitches is use
as a fail-safe switch to control replication of virus-based therapies,
such as oncolytic and live vaccine viruses, to enhance their safety.
The TC-83 live virus vaccine for protection against VEEV is only
administered to at risk military and laboratory personnel because it
causes side effects in about 40% of vaccinated people with symptoms
typical of natural VEEV infection, including fever, myalgia, nausea,
and leukopenia (Alevizatos et al., 1967). It would be beneﬁcial to
engineer a riboswitch in the 30 UTR of the virus genome so that if a
patient has a severe side effect to the vaccine, replication of the virus
can be regulated by administering a small molecule to trigger
the riboswitch. To test the ability of riboswitches to control virus
replication, the ON and OFF switches or the inactive ribozyme control
were ﬁrst inserted into the 30 UTR of the DNA-launched TC-83 virus
genome (Fig. S3A). Virus was generated by transfection of the DNA-
launched genome into BHK cells and subsequently collected in the
supernatant. BHK cells were then infected with the viruses at an MOI
of 0.01 and treated with or without theophylline to determine its
effect on viral replication over time. No difference in replication was
observed for the viruses containing either 1 or 2 copies of the ON
switch L2b8-a1 (Fig. S3B), while a 10-fold decrease in replication was
observed for the virus containing 1 copy of the OFF switch L2bOFF1
with addition of theophylline (Fig. S3C). Surprisingly, this response to
theophylline was not enhanced by insertion of additional OFF
switches into the 30 UTR (Fig. S3C). Sequencing of the RNA genomes
from progeny virus preparations revealed that the virus containing
either the inactive ribozyme control or 1 copy of the OFF switch
L2bOFF1 maintained the correct riboswitch sequence when grown in
the absence of theophylline. However, viruses containing the ON
switches had spontaneous deletions within the riboswitch sequences
(Fig. S4), even though these viruses were generated in the presence
of theophylline that should have prevented riboswitch cleavage.
These data suggest that even under these conditions the background
level of cleavage is sufﬁcient to provide selective pressure to mutate
the riboswitch sequence to inactive ribozyme activity and enhance
viral replication. In addition, sequencing of the virus containing
3 copies of the OFF switch showed that 2 of these copies were
removed, likely due to recombination (Fig. S4). This explains why this
virus did not show enhanced downregulation in replication with
addition of theophylline compared to the virus containing 1 copy of
the OFF switch (Fig. S3C).
To further enhance the regulation of virus replication and prevent
spontaneous mutation of the riboswitch sequence, we inserted the
OFF switch L2bOFF1 into both the 30 and 50 UTR of the subgenomic
RNA region (Fig. 5A). A control virus was also generated that contains
the inactive ribozyme in both the 30 and 50 UTR of the subgenomic
RNA region. Sequencing analysis conﬁrmed that the L2bOFF1 ribos-
witches in both the 30 and 50 UTR were intact and no mutations were
observed (Fig. S5). In addition, the control virus containing the inactive
ribozyme in the 30 and 50 UTR also showed the correct sequence
(Fig. S5). These viruses were then added to BHK cells and treated with
or without theophylline. Samples of the supernatants were collected
at different times postinfection and titered by plaque assay. Without
theophylline, the virus containing the OFF switches in the 30 and 50
UTR (OFF 5030) grew indistinguishably from the control virus (Fig. 5B).
With theophylline addition, the titer of the OFF 5030 virus was reduced
by 1160-fold at 12 h postinfection. To test if similar regulation of viral
replication could be observed in cells capable of generating an innate
immune response, we infected MEF cells with these viruses and
treated the cells with or without theophylline. Although there was a
delay in viral replication compared to infection of BHK cells, compar-
able results were observed in that the OFF 5030 virus showed a
signiﬁcant decrease in titer with theophylline treatment (Fig. S6).
To investigate the mechanism of the observed shutdown of viral
replication, BHK cells were collected at 12 h postinfection and assayed
for expression of viral dsRNA and viral proteins by ﬂow cytometry
(Fig. 5C and D). The percentage of dsRNA and viral protein positive
cells was reduced 20-fold by theophylline treatment, suggesting that
the switch modulates the launch of RNA replication or production of
infectious progeny (Fig. 5C). This is consistent with the data observed
for VRP infection in which the copy number of replicon RNAs was
decreased upon theophylline treatment (Fig. S1A and B). In cells
positive for dsRNA, the amount of dsRNA present (measured by mean
ﬂuorescence intensity, MFI) was similar for cells treated with and
without theophylline (Fig. 5D). This suggests that once viral RNA
replication was launched, the ribozyme-mediated cleavage does not
substantially impact replication of viral RNA. However, the amount of
viral proteins was markedly decreased in cells treated with theophyl-
line, indicating that ribozyme cleavage compromises the RNA tem-
plates for viral protein synthesis (Fig. 5D).
We next sought to determine whether viral replication could be
shut down after active infection was already established. BHK cells
were infected with the OFF 5030 virus or the control virus containing
the inactive ribozyme and incubated for 12 h. Cells were then treated
with or without theophylline and samples of the supernatants were
collected every 2 h and assayed for viral titers. Prior to theophylline
treatment, the titers of the OFF 5030 virus were similar to the control
virus (Fig. 5E). Addition of theophylline led to a signiﬁcant down-
regulation in replication of the OFF 5030 virus, with a 37-fold decrease
in titer compared to the untreated virus at 10 h after theophylline
treatment (Fig. 5E). We also analyzed expression of viral dsRNA and
proteins in infected cells by ﬂow cytometry at both 0 and 8 h
posttheophylline addition. The percentage of positive cells for both
dsRNA and viral proteins were similar and were not decreased by
addition of theophylline 8 h posttreatment (Fig. 5F). This was expected
because viral infection was already established and therefore unlikely
to be cleared from the cells after 8 h. The reduction of dsRNA levels in
positive cells by theophylline addition was minimal, but the reduction
of viral protein levels was pronounced (Fig. 5G). This suggests that
theophylline treatment activated the riboswitches to cleave the viral
RNA and reduce viral protein expression. Together, our data illustrate
that riboswitches can be used to control viral replication and support
their use as safety switches for live virus vaccines.
Discussion
The studies we describe here demonstrate that gene expression
from a positive-strand RNA virus genome can be regulated with
riboswitches. Addition of these ribozyme–aptamer switches into the
30 UTR of the replicon allows controllable cleavage of both the genomic
RNA and the subgenomic RNA, leading to stringent control of expres-
sion. This regulation can be achieved for both DNA-launched and VRP-
packaged replicons, as well as for virus. Both ON and OFF switching of
expression was achieved, demonstrating the ﬂexibility of this platform
and the ease with which one type of switch can be swapped for
another. In fact, we demonstrated that a different ribozyme (fromHDV)
that employs an alternative mechanism of aptamer-mediated regula-
tion could be used to control replicon gene expression (Fig. S2). This
opens the possibility that as new aptamer sequences that bind
molecules more relevant for use in clinical studies are discovered,
riboswitches based on these aptamers can be engineered to control
gene expression from the replicon.
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Among the riboswitches tested in this study, the ON switch L2b8-
a1 showed the most efﬁcient regulation of gene expression, with an
impressive 47-fold enhancement in expression in response to theo-
phylline in a construct that contained 2 copies of the switch (Fig. 2C).
The improvement achieved by increasing the copy number of the
switch was due to a very low background of expression in the absence
of theophylline. The L2b8-a1 switch was identiﬁed by high-
throughput screening of a randomized library of riboswitch sequences
with mutations in the actuator domain of the ribozyme (Liang et al.,
2012). Speciﬁc mutations in loop I of the ribozyme structure were
shown to lower basal expression due to faster cleavage rates compared
to the parent ribozyme sequence (Liang et al., 2012). This enhanced
ribozyme ability proved to be critical for our replicon system, as it
likely overcame the robust RNA replication rate characteristic of these
replicons. This prominent regulation of expression shows promise for
the use of this platform in a novel prime-boost vaccination regimen,
where drastic changes in antigen expression are likely necessary for
modulation of the resultant immune responses.
We have shown that both DNA-launched and VRP-packaged
switch-containing replicons could be efﬁciently regulated by theophyl-
line treatment. However, these two methods of delivery have various
pros and cons for use in prime-boost vaccination. DNA-launched
replicons will be continuously transcribed by DNA-transfected target
cells, and thus newly synthesized RNA transcripts are expected to be
Fig. 5. TC-83 virus replication can be controlled by theophylline-dependent riboswitches. (A) Schematic showing insertion of riboswitches into both the 30 and 50 UTR of the
viral subgenomic RNA. (B) BHK cells were infected at an MOI of 0.01 with a TC-83 virus containing either an inactive sTRSV ribozyme or the L2bOFF1 riboswitch in the 30 and
50 UTR of the subgenomic RNA, and treated with or without 4 mM theophylline. Samples of the supernatant were collected over time and assayed for viral titer. 0 h
postinfection indicates the titer of the input virus. (C, D) Cells were collected at 12 h postinfection and assayed for expression of dsRNA and viral proteins by ﬂow cytometry.
Data for the virus containing the L2bOFF1 5030 switches is shown normalized to the inactive ribozyme control virus for both (C) % positive cells and (D) MFI of the positive
cells. (E) BHK cells were infected with the indicated viruses at an MOI of 0.01 and incubated for 12 h. Cells were then treated with or without 4 mM theophylline and samples
of the supernatant were collected overtime and assayed for viral titer. (F, G) Cells were collected at both 0 and 8 h posttheophylline addition and assayed for expression of
dsRNA and viral proteins by ﬂow cytometry. Data for the virus containing the L2bOFF1 5030 switches is shown normalized to the inactive ribozyme control virus for both (F) %
positive cells and (G) MFI of the positive cells. “þ” indicates addition of 4 mM theophylline; “” indicates addition of media alone. **Po0.001.
C.L. Bell et al. / Virology 483 (2015) 302–311308
available for theophylline-dependent regulation of expression. This
may allow for modulation of the immune response over time, as
demonstrated by the in vitro regulation of the IFN response (Fig. 4C).
In contrast, VRP-packaged replicons deliver RNA directly to the
cytoplasm of target cells, where replication can initiate without the
need for nuclear delivery. Once the delivered RNA is cleaved, it loses
the ability to launch its replication and express proteins, and the
process is irreversible. However, the ability to regulate gene expression
from VRP-packaged replicons can be beneﬁcial for efﬁcient prime and
boost of the immune response by controlling the length of antigen
expression. It has been shown that persistent antigen expression can
hinder the immune response by causing tolerance to the antigen due
to T-cell anergy and dysfunction (den Boer et al., 2001; Han et al.,
2010). We have observed that replicon expression can last as long as
21 days postinjection when delivered as a VRP-packaged replicon
(Geall et al., 2012). Therefore, shutting down initial antigen expression
at an earlier time point using a riboswitch may lead to enhanced
immune responses upon boost. Furthermore, direct RNA delivery of
replicons may be a safer approach than DNA delivery, as it eliminates
the risk of integrating replicon sequences into the cellular genome.
Regardless, both systems of delivery provide effective regulation of
gene expression and may lead to novel methods of immune
modulation.
This is the ﬁrst study to demonstrate the use of riboswitches to
regulate replication of a positive-strand RNA virus. An attractive
application of this approach is to provide a safety switch to
terminate or control replication of live virus vaccines in the case
that a patient has a severe side effect. Mechanistically, we found
that the type and location of the riboswitch in the viral genome
had a critical effect on the efﬁciency of regulation. The ON switch
L2b8-a1 could not be successfully inserted into the 30 UTR of the
viral genome due to rapid spontaneous mutations that inactivated
the ribozyme (Fig. S4). We hypothesized that the virus needs to
overcome the baseline ribozyme activity of the switch in the
absence of theophylline by generating these escape mutations. In
addition, we failed to insert multiple copies of an OFF riboswitch
in tandem in the viral 30 UTR, as the virus spontaneously deleted
the extra copies of the switch, likely due to recombination
(Fig. S4). However, we showed that inserting an additional copy
of this riboswitch into the 50 UTR of the subgenomic RNA could
prevent this unwanted deletion, likely because recombination
would have discarded the structural proteins (Fig. S5). Together,
these results suggest that the OFF switch is effective for use in
regulation of viral replication and, if multiple copies of a ribos-
witch are needed, measures need to be taken to prevent unwanted
deletion of the repeat sequences.
Although virus replication was substantially hindered by ribos-
witch activation, our data suggests that some virions were still
able to establish infection (Fig. 5B and E). It is possible that this is
the result of escape mutants that are generated when theophylline
is added immediately upon infection (Fig. 5B). If one riboswitch is
mutated, the remaining switch would not be able to efﬁciently
suppress viral replication (Fig. S3C). Alternatively, it is possible
that a small fraction of quasispecies are present within the virus
stock which can replicate in the presence of theophylline. How-
ever, the model in Fig. 5E is likely more representative of the real-
world application of these riboswitches for control of viral replica-
tion. In this experiment, it was also observed that some residual
viral replication was still able to occur after theophylline addition
(Fig. 5E). Since viral replication was so robust at the time theophyl-
line was added, it is possible that riboswitch-mediated cleavage
could not completely overcome the rapidity of viral replication.
Nonetheless, complete shut-down of viral replication may not be
necessary for the immune system to control the infection. In the
case of a severe reaction to a live virus vaccine, the high degree of
riboswitch-mediated inhibition of viral replication would likely
allow the immune system to overcome the infection and manage
the adverse response.
In summary, the use of engineered riboswitches for control of
RNA replicon expression and viral replication holds promise for
novel and safer vaccination strategies. This platform may also
potentially be utilized in gene therapy applications to provide
robust gene expression that can be regulated as required to
achieve reprogramming of cells for various applications, such as
adoptive cell therapies and generation of induced pluripotent stem
cells (Yoshioka et al., 2013). In future studies, engineering apta-
mers that bind to molecules safe and effective to use in patients
will be crucial for the development of riboswitches for clinical use.
Materials and Methods
Cell lines
Baby hamster kidney (BHK) cells were cultured in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) (HyClone) supplemented with 5%
FBS (Omega Scientiﬁc), 1% L-glutamine (Corning), and 1% penicillin/
streptomycin (Corning). p53 knock-out mouse embryonic ﬁbroblast
(MEF) cells were cultured in DMEM supplemented with 10% FBS, 1%
L-glutamine, and 1% penicillin/streptomycin. Cells were grown at
37 1C with 5% CO2.
Plasmids
Replicons used in this study were based on the VEEV vaccine
strain TC-83, with the viral structural genes replaced by the secreted
alkaline phosphatase (SEAP) gene (Perri et al., 2003). To generate the
DNA plasmid expressing this replicon, the cytomegalovirus (CMV)
immediate early gene promoter was cloned into the plasmid
preceding the replicon sequence to drive the transcription of replicon
RNA with the expected 50 UTR sequence. A hepatitis delta virus
(HDV) ribozyme, present at the end of the replicon polyA sequence,
ensures the generation of a proper 30 end following cellular tran-
scription. In addition, a BGH polyA sequence is included to facilitate
nuclear export. Riboswitches were inserted into the region between
the end of the SEAP gene and the start of the TC-83 30 UTR and were
ﬂanked by spacer sequences to prevent unwanted interactions with
the surrounding replicon sequences (50 ﬂanking sequence: 50 AAA-
CAAACAAA 30; 30 ﬂanking sequence: 50 AAAAAGAAAAATAAAAA 30).
The sequences of the active and inactive sTRSV ribozymes and the
riboswitches L2b8 and L2bOFF1 are described in (Win and Smolke,
2007). The sequence of the riboswitch L2b8-a1 is described in (Liang
et al., 2012). The sequences of the active and inactive HDV genomic
ribozyme and the riboswitch Theo6HDV are described in (Nomura
et al., 2013). For some replicons in this study, multiple copies of a
riboswitch were inserted, with each switch being separated by 10
thymine bases. For plasmids producing TC-83 virus, the SEAP gene
was replaced by the TC-83 capsid and glycoprotein genes. Addition of
the L2bOFF1 riboswitch into the 50 UTR of the viral subgenomic RNA
was performed using the same spacer regions as described above,
with insertion 26 bases after the start of the subgenomic RNA region.
Transfection of DNA-launched TC-83 replicons
Plasmids carrying DNA-launched replicons were transfected into
BHK cells at 4 mg of DNA per 106 cells by using Lipofectamine 2000
(Life Technologies). Transfected cells were plated into 6-well plates
and incubated at 37 1C for 6 h. Mediawere then removed and replaced
with fresh DMEMwith 5% FBS and cultures were incubated overnight.
Twenty-four hours after transfection, cells were treated with or
without 4 mM theophylline (Sigma-Aldrich) in DMEM with 5% FBS
C.L. Bell et al. / Virology 483 (2015) 302–311 309
and culture supernatants were collected at the indicated timepoints to
determine SEAP expression.
VRP generation and infection
Viral replicon particles (VRPs) were generated by triple trans-
fection of a plasmid containing the DNA-launched replicon, a
plasmid expressing the TC-83 capsid protein, and a plasmid
expressing the TC-83 glycoproteins into BHK cells, by using
Lipofectamine 2000. Six hours after transfection, media were
removed and replaced with DMEM with 1% FBS, supplemented
with 4 mM theophylline for the generation of VRPs containing ON
switches, and cell cultures were incubated overnight. The next day,
VRP-containing medium supernatant was collected, cell debris
was spun out, and VRPs were stored at 80 1C. To titer the VRPs,
BHK cells were plated into 96-well plates at 50,000 cells/well. Ten-
fold serial dilutions of VRPs were added to the cells and incubated
at 37 1C overnight. The next day, cells were washed and ﬁxed with
acetone/methanol and blocked with PBSþ2% normal goat serum
(Jackson ImmunoResearch). Cells were then stained for TC-83
using polyclonal anti-VEEV hyperimmune ascitic ﬂuid, followed
by a peroxidase-conjugated Afﬁni Pure goat anti-mouse IgG
secondary antibody (Jackson ImmunoResearch). Cells were then
treated with TrueBlue peroxidase substrate (KPL) and positive cells
were counted using a hemocytometer to determine the infectious
units (IU)/ml. For infection studies, VRPs were added to BHK cells
at a multiplicity of infection (MOI) of 0.1 and cells were treated
with or without 4 mM theophylline in DMEM, 1% FBS. VRPs were
incubated on the cells overnight and supernatants were collected
at the indicated timepoints to determine SEAP expression.
SEAP expression
SEAP expressionwas determined using the Great EscAPe™ SEAP kit
(Clontech). Brieﬂy, supernatants were diluted 1:100 and 12.5 ml was
added to 37.5 ml of 1X dilution buffer and incubated at 65 1C for
30 min. Then, 50 ml of SEAP substrate solution was added and
incubated at room temperature for 30 min. Luminescence was deter-
mined using a Centro LB 960 microplate luminometer (Berthold
Technologies).
Determination of RNA copy number
BHK cells were infected with VRPs expressing EGFP at an MOI of
0.1 and the cells were treated with or without 4 mM theophylline in
DMEM, 1% FBS. Infected cells were collected by trypsinization at the
indicated timepoints. RNA was extracted from cells with TRIzol (Life
Technologies) using a slight modiﬁcation of the method recom-
mended by the manufacturer, and resuspended in 30 ml of nuclease-
free water. RNA was then treated with TURBO DNase (Ambion) for
30 min at 37 1C and puriﬁed using the RNeasy Mini Kit (Qiagen). cDNA
was generated using the iScript cDNA Synthesis Kit (Bio-Rad) using
250 ng of RNA as template. Copy number was then determined using
droplet digital PCR. For subgenomic RNA, a probe and a pair of primers
speciﬁc to the EGFP sequence were used (probe: HEX-50 CATCGACTT-
CAAGGAGGACGGCAACATC 30; F primer: 50 CACCATCTTCTTCAAGGAC
30; R primer: 50 GTAGTTGTACTCCAGCTTG 30). (This probe and primer
set measured both genomic and subgenomic transcripts due to their
co-linear nature, but subgenomic transcripts represented the majority
of the signal detected). For genomic RNA, a probe and a pair of primers
speciﬁc to NSP3 were used (probe: FAM-50 TGGTCCATTCCTCATG-
CATCCGA 30; F primer: 50 CCGCCCTCTGTATCTAGCTCATC 30; R primer:
50 CCCTCCAGGGTGTCAAGTATG 30). Droplets were generated using the
QX200 droplet generator (Bio-Rad) and PCR performed using a T100
Thermal Cycler (Bio-Rad) by following the manufacturer's protocol.
Results were read using the QX200 Droplet Reader (Bio-Rad) and data
was analyzed using the QuantaSoft program.
Determination of type I IFN response
MEF cells were transduced with a lentiviral vector expressing
the ﬁreﬂy luciferase gene under the control of a minimal CMV
promoter and tandem repeats of the IFN-stimulated response
element (ISRE) using the Cignal Lenti ISRE Reporter kit (Qiagen).
Stably transduced cells were selected with puromycin. Cells were
then either transfected with 4 mg of DNA-launched replicons or
infected with VRP-packaged replicons at an MOI of 1 and treated
with or without 4 mM theophylline in black-walled 96-well plates.
The type I IFN response was determined by measuring luciferase
expression. In brief, D-luciferin (PerkinElmer) diluted to 150 mg/ml
in DMEM and added to the cells at 100 ml/well. Luminescence was
read using a Centro LB 960 microplate luminometer.
Recombinant TC-83 virus generation and titration
Plasmids encoding DNA-launched TC-83 viral genomes were
transfected into BHK cells at 4 mg of DNA per 106 cells by using
Lipofectamine 2000. Six hours after transfection, media were
removed and replaced with DMEM containing 1% FBS, supple-
mented with 4 mM theophylline for the generation of viruses
containing ON switches, and incubated overnight. The next day,
supernatant containing virus was collected, cell debris was spun
out, and virus was stored at 80 1C. To titer viruses by plaque
assay, BHK cells were plated into 24-well plates at 200,000 cells/
well. Ten-fold serial dilutions of virus were added to the cells and
incubated at 37 1C for 1 h. Then, virus was removed and 1 ml of a
solution containing 1.2% carboxymethyl cellulose (Sigma) dis-
solved in Eagle's Minimum Essential Medium (Lonza) supplemen-
ted with 2% FBS, L-glutamine, and penicillin/streptomycin was
added to the cells. After incubation at 37 1C for 48 h, cells were
ﬁxed by adding 1 ml of 10% formalin and incubating at room
temperature for 20 min. Formalin was removed and cells were
washed with water and then stained with 0.5 ml of 1% crystal
violet (Sigma-Aldrich) in 30% ethanol at room temperature for
30 min. Cells were then washed again with water, air-dried, and
plaques were counted to determine the PFU/ml. To infect BHK or
MEF cells, virus was added at an MOI of 0.01 in DMEM with 1% FBS
and treated with or without 4 mM theophylline. Supernatants
were collected at the indicated timepoints and viral titers were
determined by plaque assay.
Flow cytometry
Virus-infected cells were collected at the indicated timepoints,
centrifuged, and washed with staining buffer (1X PBSþ0.25%
BSAþ0.2% NaN3). Cells were resuspended in 100 ml of cytoﬁx/
cytoperm (BD) and incubated at 4 1C for 20 min. Cells were then
washed 2X with 200 ml of perm/wash buffer (BD), stained with
either the J2 anti-dsRNA IgG2a monoclonal antibody (Scicons)
(Bonin et al., 2000; Schonborn et al., 1991) or polyclonal anti-VEEV
hyperimmune ascitic ﬂuid using the Zenon allophycocyanin (APC)
mouse IgG2a labeling kit (Life Technologies), and incubated at 4 1C
for 30 min. Cells were then washed again 2X with perm/wash
buffer followed by 2X with staining buffer, resuspended in 300 ml
staining buffer, and evaluated using a BD FACSCalibur. Data was
analyzed using FlowJo software.
Virus genome sequencing
Viruses generated after DNA transfection into BHK cells (as
described above) were analyzed by direct sequencing. Viral RNA
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was isolated by mixing 100 ml of virus-containing supernatant
ﬂuid with 900 ml of TRIzol (Life Technologies) and incubating at
4 1C for 5 min. Then, 100 ml of chloroform was added and the
emulsion was vortexed vigorously and spun down at 12,000 rpm
at 4 1C for 10 min. The upper phase was transferred to a new tube
and mixed with 400 ml chloroform and spun down again. The
upper phase was again removed and mixed with 350 ml of
isopropanol and incubated at 20 1C for 30 min and centrifuged
at 12,000 rpm for 10 min. RNA pellets were washed with 70%
ethanol and resuspended in 15 ml of nuclease-free water. Next,
cDNA was generated using the Monster-Script™ 1st-strand cDNA
synthesis kit (Epicenter) according to the manufacturer's protocol.
The cDNAwas then used as a template to amplify either the 50 or 30
UTR region of the subgenomic RNA by PCR using the Q5 high-
ﬁdelity PCR kit (New England BioLabs) and PCR products were
analyzed by direct sequencing (Genewiz). Electropherograms for
each construct showed one dominant virus sequence.
Statistics
Statistical signiﬁcance was determined using Student's 2-tailed
t test. P values considered signiﬁcant are indicated in the ﬁgure
legends. Data are represented as mean7SD.
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